WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) reported that its second quarter net income attributable to Royalty Pharma declined to $18 million from $32 million, last year. Adjusted EBITDA increased to $736 million from $633 million. Total income and other revenues was $674 million compared to $579 million.
Royalty Receipts grew 14% to $768 million, driven by Tremfya, Voranigo, Imdelltra and Evrysdi. Portfolio Receipts increased by 6% to $773 million, reflecting lower milestones and other contractual receipts.
Royalty Pharma now expects 2026 Portfolio Receipts to be between $3.400 billion and $3.500 billion, revised from prior outlook of $3.325 billion to $3.450 billion, representing expected Royalty Receipts growth of 7% to 10%.
In pre-market trading on NasdaqGS, Royalty Pharma shares are up 1.17 percent to $58.15.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
